Success Metrics

Clinical Success Rate
89.8%

Based on 221 completed trials

Completion Rate
90%(221/246)
Active Trials
11(4%)
Results Posted
65%(144 trials)
Terminated
25(9%)

Phase Distribution

Ph not_applicable
25
9%
Ph early_phase_1
2
1%
Ph phase_4
94
32%
Ph phase_1
27
9%
Ph phase_2
44
15%
Ph phase_3
84
29%

Phase Distribution

29

Early Stage

44

Mid Stage

178

Late Stage

Phase Distribution276 total trials
Early Phase 1First-in-human
2(0.7%)
Phase 1Safety & dosage
27(9.8%)
Phase 2Efficacy & side effects
44(15.9%)
Phase 3Large-scale testing
84(30.4%)
Phase 4Post-market surveillance
94(34.1%)
N/ANon-phased studies
25(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.7%

221 of 255 finished

Non-Completion Rate

13.3%

34 ended early

Currently Active

11

trials recruiting

Total Trials

294

all time

Status Distribution
Active(12)
Completed(221)
Terminated(34)
Other(27)

Detailed Status

Completed221
unknown27
Terminated25
Withdrawn9
Recruiting7
Active, not recruiting4

Development Timeline

Analytics

Development Status

Total Trials
294
Active
11
Success Rate
89.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (0.7%)
Phase 127 (9.8%)
Phase 244 (15.9%)
Phase 384 (30.4%)
Phase 494 (34.1%)
N/A25 (9.1%)

Trials by Status

completed22175%
not_yet_recruiting10%
terminated259%
active_not_recruiting41%
unknown279%
recruiting72%
withdrawn93%

Recent Activity

Clinical Trials (294)

Showing 20 of 294 trialsScroll for more
NCT07634380Phase 1

Sitagliptin With Pembro in RCC and Melanoma

Recruiting
NCT02363335Phase 1

The Role of Phosphodiesterase Inhibitors in Incretin Secretion

Completed
NCT07717242Phase 2

Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

Recruiting
NCT07567781Phase 1

A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

Active Not Recruiting
NCT07711171Phase 4

Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment

Recruiting
NCT07417631

Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.

Completed
NCT07599345

Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data

Completed
NCT07417618

INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)

Completed
NCT07599293

Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data

Completed
NCT07390110

Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)

Active Not Recruiting
NCT07003542Phase 2

A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas

Recruiting
NCT07541781Phase 1

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

Recruiting
NCT06246799Phase 3

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Recruiting
NCT06851962Phase 4

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

Active Not Recruiting
NCT06263673Phase 4

Anti-Diabetic Medications to Fight PD and LBD

Completed
NCT07096063

Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

Completed
NCT02650427Phase 1

A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection

Completed
NCT03738878Phase 4

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Terminated
NCT02879409Not Applicable

HbA1c Variability in Type II Diabetes

Active Not Recruiting
NCT06659718

Emulation of the SOUL Diabetes Trial in Healthcare Claims

Completed

Drug Details

Intervention Type
DRUG
Total Trials
294